Navigation Links
ULURU Inc. Reports Third Quarter 2010 Financial Results

ADDISON, Texas, Nov. 15, 2010 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced its financial results for the third quarter ended September 30, 2010.

For the third quarter of 2010, the Company reported a net loss of $1.2 million, or $0.01 per share, compared with a net loss of $1.5 million, or $0.02 per share, for the same period last year.  For the nine months ended September 30, 2010, the Company reported a net loss of $4.7 million, or $0.06 per share, compared with a net loss of $7.5 million, or $0.11 per share, for the same period last year.  At September 30, 2010, the Company held cash and cash equivalents of $1.3 million, compared with $1.9 million at December 31, 2009.

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "Financial performance is substantially in line with our plan for the quarter.  Revenues from U.S. Altrazeal® sales were below forecasted levels primarily due to a reduction in wholesaler inventory levels, reflecting our ability to supply product immediately on receipt of an order, and reduced hospital patient visits which have returned to normal levels in October.  We continue to closely control our expenses and prioritize our investments to those projects which are expected to yield the highest returns."

Mr. Gray continued, "Substantial progress has been made on many fronts in the third quarter, including:

  • Execution of a worldwide animal health distribution agreement;
  • Realigning our sales and marketing activities to focus on diabetic foot ulcers, venous ulcers, and geriatric wounds where we have excellent clinical evidence supporting cost effective treatment with Altrazeal®;
  • Advancing the product pipeline, including working to resolve issues with our silver product, planning a clinical study with our collagen product, and finalizing plans for our 0.75 gram line extension;
  • Successfully completing 150 audits, essential to maintaining our CE Mark approval;
  • Expanding and advancing discussions on numerous strategic partnering opportunities;
  • Planning for the launch of multiple products in international markets in early 2011; and
  • Upgrading our independent sales force and substantially expanding the number of representatives.

  • We believe that the recent progress that has been made will begin to favorably impact our financial results in the fourth quarter, with the major impact being experienced in 2011."

    Operating ResultsRevenues

    Revenue for the third quarter of 2010 was $62,000, compared to $130,000 for the third quarter of 2009.  The decrease of $68,000 in revenue was due primarily to a decrease of $25,000 in OraDisc™ licensing fees due to an adjustment in revenue amortization and the impact of the divestiture of Zindaclin® technologies in June 2010, which resulted in decreases of $2,000 in licensing and $39,000 in royalties.

    Research and Development

    Research and development expenses for the third quarter of 2010 were $296,000, including $32,000 in share-based compensation, compared to $376,000, including $31,000 in share-based compensation, for the third quarter of 2009.  The decrease of $80,000 in research and development expenses consisted of decreases in scientific personnel costs of $34,000, regulatory consulting expenses of $11,000, direct research costs of $8,000, and clinical testing expenses for our wound care technologies of $29,000.  

    Selling, General and Administrative

    Selling, general and administrative expenses for the third quarter of 2010 were $666,000, including $26,000 in share-based compensation, compared to $981,000, including $126,000 in share-based compensation, for the third quarter of 2009.  The decrease of approximately $315,000 in selling, general and administrative expenses reflects the Company's restructured business plan which contributed to a decrease of $164,000 in administrative compensation, lower legal fees of $134,000, lower legal fees related to our patents of $30,000, lower consulting fees of $28,000, a decrease in travel expenses of $15,000, and a decrease of $13,000 in insurance expense.  These expense decreases were partially offset by an increase in director fees of $64,000, a component of share-based compensation.

    Other income and Other expenses

    Interest and miscellaneous income for the third quarter of 2010 was $4,800 as compared to $6,700 for the third quarter of 2009.  The decrease of $1,900 is attributable to a decrease in interest income due to lower cash balances and interest yields in 2010.

    Interest expense for the third quarter of 2010 was $21,000 as compared to $2,000 for the third quarter of 2009.  Interest expense for the third quarter of 2010 consisted of financing costs for our insurance policies and interest costs associated with regulatory fees.  

    About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at  For further information about Altrazeal®, please visit our website at

    This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the anticipated benefits of our marketing strategy being realized in the fourth quarter of 2010 and for 2011, the launch of products in early 2011, the hiring of additional sales representatives, and the establishment of future business partnerships.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. GrayPresident & CEOTerry K. WallbergVice President & CFO(214) 905-5145ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATAThree Months Ended September 30,Nine Months Ended September 30,2010200920102009REVENUESLicense fees

    4,370$   22,979$  150,283$  72,555Royalty income

    23,10461,727132,473204,830Product sales, net


    ---6,000---38,190Total Revenues

    61,617130,234528,481435,057COSTS AND EXPENSESCost of goods sold

    6,4167,785143,25922,783Research and development

    295,781376,191948,9602,006,070Selling, general and administrative

    666,205981,2122,405,1235,041,318Amortization of intangible assets


    79,07346,424179,053126,002Total Costs and Expenses

    1,253,9291,683,7144,375,6478,003,724OPERATING (LOSS)( 1,192,312)( 1,553,480)(3,847,166)(7,568,667)Other Income (Expense)Interest and miscellaneous income

    4,8406,6765,55542,296Interest expense

    (20,650)(1,926)(37,138)(1,926)Loss on sale of intangible asset

    ------( 857,839)---Loss on sale of equipment

    ---------(2,121)(LOSS) BEFORE INCOME TAXES(1,208,122)( 1,548,730)(4,736,588)(7,530,418)Income taxes

    ------------NET (LOSS)$(1,208,122)$(1,548,730)$ (4,736,588)$ (7,530,418)Basic and diluted net (loss) per common share

    $   (0.01)$   (0.02)$  (0.06)$  (0.11)WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

    82,084,31666,038,07981,346,13865,723,998ULURU Inc. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATASeptember 30, 2010December 31, 2009(Unaudited)(Audited)  Cash and cash equivalents

    ,934,177  Current assets

    2,904,0613,544,850  Property and equipment, net

    1,452,5041,631,557  Other assets

    5,853,4168,203,965  Total assets

    10,209,98113,380,372  Current liabilities

    1,149,342929,771  Long term liabilities – deferred revenue

    1,461,9021,272,843  Total liabilities

    2,611,2442,202,614  Total stockholders' equity


    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
    2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
    3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
    4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
    5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
    6. ULURU Inc. Reports Second Quarter 2010 Financial Results
    7. ULURU Inc. Announces Conference Call
    8. ULURU Inc. Provides Altrazeal® Clinical Update
    9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    10. Spherix Reports Second Quarter Earnings
    11. Tapestry Reports Second Quarter 2007 Results
    Post Your Comments:
    (Date:11/29/2015)... Nov. 29, 2015 CIVCO Medical Solutions ... at the Radiological Society of North ... Chicago November 29 – December 4, ... to offer customers unrivaled versatility, enhanced user experience ... --> ...
    (Date:11/27/2015)... 27, 2015 Une nouvelle ... au Bremachlorin contre le cancer avancé.    ... combiner l,immunothérapie au traitement photodynamique au Bremachlorin contre ... Une nouvelle approche consistant à combiner l,immunothérapie ... avancé.    Clinical Cancer Research ...
    (Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
    (Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
    (Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
    Breaking Medicine News(10 mins):